Schwab Charles Investment Management Inc. lifted its position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 10.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 152,668 shares of the company’s stock after purchasing an additional 14,379 shares during the period. Schwab Charles Investment Management Inc. owned 0.42% of Aerie Pharmaceuticals worth $7,420,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in AERI. Rhumbline Advisers increased its stake in shares of Aerie Pharmaceuticals by 3.7% during the 2nd quarter. Rhumbline Advisers now owns 34,913 shares of the company’s stock worth $1,835,000 after purchasing an additional 1,237 shares during the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Aerie Pharmaceuticals during the 2nd quarter worth about $1,209,000. Bank of New York Mellon Corp increased its stake in shares of Aerie Pharmaceuticals by 64.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 436,955 shares of the company’s stock worth $22,962,000 after purchasing an additional 171,879 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Aerie Pharmaceuticals by 7.4% during the 2nd quarter. Legal & General Group Plc now owns 7,534 shares of the company’s stock worth $396,000 after purchasing an additional 519 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock worth $195,000 after purchasing an additional 3,579 shares during the last quarter.

Several research firms have recently weighed in on AERI. Canaccord Genuity restated a “positive” rating and set a $73.00 price objective (up from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Needham & Company LLC reiterated a “buy” rating and issued a $76.00 price target (up previously from $65.00) on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Guggenheim started coverage on shares of Aerie Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $80.00 price target on the stock. Mizuho reiterated a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Monday, October 16th. Finally, JMP Securities set a $68.00 price target on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company. Aerie Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $72.00.

Aerie Pharmaceuticals Inc (AERI) opened at $60.60 on Friday. Aerie Pharmaceuticals Inc has a 52 week low of $37.80 and a 52 week high of $66.60. The company has a market cap of $2,222.47, a PE ratio of -18.14 and a beta of 1.11. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/schwab-charles-investment-management-inc-has-7-42-million-holdings-in-aerie-pharmaceuticals-inc-aeri/1795155.html.

Aerie Pharmaceuticals Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.